Most effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline says Certain GLP-1 drugs are best for specific complications The non-binding guideline ...

FILE PHOTO: FA combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File ...

Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in ...

A sign for Eli Lilly and Company sits outside its corporate headquarters in Indianapolis on April 26, 2017. Pharmaceutical corporation Eli Lilly and Company plans to build a $6.5 billion manufacturing ...

Sept 25 (Reuters) - Eli Lilly (LLY.N), opens new tab has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, ...

IN recent months makers of weight-loss drugs have gone on a crash diet. In late July Novo Nordisk, the Danish firm that gave the world Ozempic, lost a quarter of its market value in a day after it cut ...

While Eli Lilly is rethinking its biotech incubator plans in Europe, the Big Pharma has gone ahead and opened its San Diego site. The Gateway Labs are co-working spaces for researchers that also act ...

UNSW Sydney provides funding as a member of The Conversation AU. Every few years, the concept of fasted exercise training pops up all over social media. Fasted training refers to exercising in the ...

Eli Lilly is planting a flag in Houston with a $6.5 billion biomanufacturing complex, the biggest biotech investment in Texas history and one of the largest single corporate projects ever in the ...

Eli Lilly’s valuation has compressed significantly from last year’s highs, despite fundamentals improving faster than its share price. Industry-leading incretin treatments (Mounjaro, Zepbound) are ...